GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide
NCT ID: NCT03845179
Last Updated: 2021-03-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2019-05-29
2020-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist
NCT03133741
Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?
NCT01048268
The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes
NCT04228484
GIP Receptor Antagonist Studies in Humans
NCT02747472
Effect of GIP After a Meal in Patients With Type 2 Diabetes
NCT03702660
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Placebo
Saline infusion
GIP receptor antagonist
Used for infusion on study days
Placebo tablet
Oral administration of placebo tablet in placebo treatment period
DPP-4 inhibitor
DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
Placebo
Saline infusion
GIP receptor antagonist
Used for infusion on study days
DPP-4 inhibitor
Oral administration of DPP-4 inhibitor in active treatment period
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Saline infusion
GIP receptor antagonist
Used for infusion on study days
DPP-4 inhibitor
Oral administration of DPP-4 inhibitor in active treatment period
Placebo tablet
Oral administration of placebo tablet in placebo treatment period
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \< 75 mmol/mol
Exclusion Criteria
* eGFR \< 60 ml/min/1,73m2
* NYHA III or IV
* anemia.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Gentofte, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Signe Stensen
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Clinical Metabolic Research
Copenhagen, Hellerup, Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stensen S, Gasbjerg LS, Rosenkilde MM, Vilsboll T, Holst JJ, Hartmann B, Christensen MB, Knop FK. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in beta-Cell Function in Patients With Type 2 Diabetes. Diabetes. 2022 Oct 1;71(10):2209-2221. doi: 10.2337/db22-0059.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-18040916
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.